Skip to content
Intellectual Property

PM(NOC) Regulations: How Section 6 Actions Work

Section 6 actions under the PM(NOC) Regulations decide whether generic and biosimilar drugs infringe listed patents. Innovators have 45 days after a notice of allegation to sue in the Federal Court, triggering a 24-month stay on approval, and must weigh section 8 damages if they lose.

Pharmaceutical packaging and court documents illustrating section 6 actions under the PM(NOC) Regulations

Key takeaways

  • Innovators must bring a section 6 action within 45 days after service of a notice of allegation.
  • Starting the action triggers a 24-month bar on the generic's notice of compliance.
  • Since 2017, section 6 proceedings are full actions that finally decide infringement and validity.
  • Section 6.01 bars later infringement suits on patents that could have been raised in the action.
  • If the action fails, plaintiffs are jointly liable for the generic's losses under section 8.

How section 6 actions work: the short answer

Section 6 actions are the main battleground for generic and biosimilar entry in Canada. Under the Patented Medicines (Notice of Compliance) Regulations (PM(NOC) Regulations), a company seeking approval of a drug by reference to an innovator's product must address the patents listed for that product. If it alleges that a listed patent is invalid or not infringed, the innovator or patent owner has 45 days after service of the notice of allegation to bring a section 6 action in the Federal Court.

Bringing the action triggers an automatic stay: Health Canada cannot issue the generic's notice of compliance (NOC) for 24 months, unless the case is resolved sooner. The action is a full trial that finally decides infringement and validity.

Pharmaceutical packaging and court documents illustrating section 6 actions under the PM(NOC) Regulations
The PM(NOC) process links drug approval to patent litigation in the Federal Court.

This full-action model has applied since amendments that came into force in September 2017 (SOR/2017-166). Before then, PM(NOC) proceedings were summary applications that only decided whether to prohibit approval, leaving infringement and validity to separate litigation. Today, section 6 actions usually produce a final judgment within the 24-month window, which gives both sides more certainty but compresses the timetable for a complex patent trial.

The patent register and listing

Everything starts with the patent register maintained by Health Canada. Under s. 4 of the Regulations, a "first person" (usually the innovator) that files a new drug submission or supplement may submit a patent list. A patent is eligible for listing only if it contains a claim for the medicinal ingredient, the formulation, the dosage form or the use of the medicinal ingredient, and the relevant ingredient, formulation, dosage form or use has been approved in the submission (s. 4(2)).

Patents generally must be listed at the time the submission is filed or, for later-issued patents with an earlier Canadian filing date, within 30 days after issuance. Certificates of supplementary protection (CSPs) can also be listed where the underlying patent is listed (s. 4(3.1)).

Listing matters because only listed patents trigger the notice requirement and the 24-month stay. A second person can ask the Federal Court, in the section 6 action, to declare that a patent or CSP is ineligible for listing (s. 6.07), but the court will not dismiss the action solely on that basis.

The notice of allegation

A "second person" (typically a generic or biosimilar manufacturer) that files a submission that directly or indirectly compares its drug with the innovator's product must address every listed patent and CSP.

The second person can either accept that it will wait for expiry or serve a notice of allegation asserting, for example, that the patent is invalid or would not be infringed. The notice must set out a detailed statement of the legal and factual basis for the allegations. The quality of the notice of allegation shapes the litigation that follows, because it frames the issues the innovator must decide whether to contest within 45 days.

Bringing section 6 actions and the 24-month stay

Under s. 6(1) of the Regulations, the first person or a patent owner who receives a notice of allegation may, within 45 days after the first person is served, bring an action in the Federal Court for a declaration that making, using or selling the generic drug in accordance with the submission would infringe any patent or CSP that is the subject of an allegation. Patent owners must be parties to the action (s. 6(2)), and the second person may counterclaim for a declaration of invalidity or non-infringement (s. 6(3)).

Under s. 7(1), the Minister may not issue the second person's NOC before the latest of several dates, including the 46th day after the notice of allegation is served and, if an action is brought, the day after a 24-month period that begins on the day the action is brought (s. 7(1)(d)). The stay ends earlier if the action is dismissed or discontinued, and the court can shorten or lengthen the 24-month period if a party has not acted diligently or has not reasonably cooperated in expediting the action.

StageProvisionTiming or rule
Patent listings. 4With the submission, or within 30 days of issuance for eligible later-issued patents
Notice of allegation serveds. 5(3)Detailed statement of legal and factual basis
Section 6 actions. 6(1)Within 45 days after service of the notice
Earliest NOC if no actions. 7(1)(c)46th day after service
Statutory stays. 7(1)(d)24 months from the day the action is brought
Case managements. 6.1Specially managed proceeding; conference soon after the 10th day after proof of service
Interlocutory appealss. 6.11To the Federal Court of Appeal with leave; motion within 10 days
Compensation to second persons. 8If the action is discontinued, dismissed or reversed on appeal

Case management, discovery and trial

Section 6 actions are specially managed proceedings under the Federal Courts Rules (s. 6.1), with a case management judge who sets a timetable designed to reach trial and judgment within the 24-month window. In practice, that means expedited documentary and oral discovery, early exchange of expert reports and a trial of one to three weeks.

Interlocutory orders can be appealed only to the Federal Court of Appeal with leave, on a motion filed within 10 days (s. 6.11). The court can dismiss an action that is redundant, frivolous, vexatious or an abuse of process (s. 6.08) and has broad discretion over costs, including solicitor-and-client costs, taking into account diligence, cooperation and the listing of ineligible patents (s. 6.12).

Because the trial is a full action, the usual patent law issues are in play: claim construction, anticipation, obviousness, sufficiency, utility (including the promise doctrine's rejection in AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36, SCC docket 36654), overbreadth and infringement. For new uses and dosing regimens, recent Supreme Court guidance on methods of medical treatment is directly relevant; see our insight on medical use and dosing regimen patents.

Practical point

For innovators, the 45-day deadline leaves little time to assess a notice of allegation, test the generic's product information and assemble experts. Prepare litigation playbooks for each listed patent before notices arrive, including likely invalidity attacks and the evidence needed to prove infringement.

Preclusion of later infringement actions

Section 6.01 bars any other infringement action against the second person in relation to its drug for a patent or CSP that was the subject of a notice of allegation, unless the first person or owner did not have a reasonable basis to bring a section 6 action within the 45-day period. Innovators therefore cannot hold back a listed patent for later damages litigation. The rule encourages comprehensive actions that put every contested listed patent before the same judge, and makes the decision whether to sue on each listed patent within 45 days an important strategic choice.

Section 8 damages for delayed generic entry

If a section 6 action is discontinued or dismissed, or a declaration of infringement is reversed on appeal, all plaintiffs are jointly and severally liable to the second person for losses suffered after the later of the date the notice of allegation was served and the date, certified by the Minister, on which the NOC would otherwise have issued (s. 8(2)). The court can choose another start date where more appropriate (s. 8(3)), may award damages as the circumstances require (s. 8(5)), and must consider all relevant matters, including any party's conduct that delayed the action (s. 8(6)).

Section 8 claims can be large, because they compensate for lost generic sales during the stay, so innovators should weigh this exposure before suing on weaker patents and keep the strength of each patent under review as the case develops.

Section 6 actions involving biosimilars

The PM(NOC) Regulations apply to biologics as well as small-molecule drugs, so biosimilar manufacturers that compare their product with a reference biologic must address listed patents in the same way. Section 6 actions involving biosimilars tend to focus on different issues: formulation and dosage form patents, methods of manufacture (which generally cannot be listed but may be litigated separately), and use patents tied to particular indications. Biosimilar sponsors often carve out indications that remain protected, and innovators must decide whether listed use patents can support an infringement case where the biosimilar's product monograph omits those uses but physicians may still prescribe them.

Because biologic patent estates are large and often include patents that are not eligible for listing, both sides should map the register against the wider portfolio. A biosimilar that clears the PM(NOC) process may still face conventional infringement actions on unlisted patents, subject to s. 6.01 for patents that were the subject of a notice of allegation.

Strategy for innovators and generics

For innovators, the main decisions are which patents to list, which allegations to contest and how to prove infringement quickly. Listing ineligible patents can attract costs consequences under s. 6.12, while failing to list eligible patents forfeits the stay. For generics and biosimilars, the main decisions are how to draft a notice of allegation that frames winnable issues, whether to seek a declaration of ineligibility, and how to preserve a section 8 claim by documenting the market they could have captured. Both sides should keep the timetable in mind: section 6 actions move fast, and evidence that is not prepared early is hard to assemble later.

Settlement considerations

Many section 6 actions settle. Settlements typically involve an agreed entry date, sometimes with a licence, supply or authorized generic arrangement. Settlement terms must be reviewed for competition law risk: agreements between an innovator and a generic that delay entry in exchange for payment can raise issues under the Competition Act, and the Competition Bureau has published guidance on patent settlements. Settlements should also address the Federal Court proceeding and the effect of discontinuance on the statutory stay, any s. 8 claim, related litigation on other patents, and the treatment of future product changes. See our pages on IP litigation and abuse of dominance and civil provisions.

How TRW & Co helps

We advise innovators, generic and biosimilar manufacturers and investors on PM(NOC) strategy and section 6 actions. We help with patent listing strategy, assessment of notices of allegation, litigation planning and expert coordination, section 8 exposure analysis and settlement structuring, working alongside Canadian-licensed litigation counsel who appear in the Federal Court. We also coordinate patent term, CSP and data protection planning for product life cycles; see our insights on certificates of supplementary protection and patent term adjustment, and our life sciences and health page. To discuss a matter, contact us. This article is general information, not legal advice.

Frequently asked questions

What is the deadline to start a section 6 action?

The first person or patent owner must bring the action in the Federal Court within 45 days after the day on which the first person is served with the notice of allegation. If no action is brought, the Minister may issue the second person's notice of compliance from the 46th day after service, subject to other conditions.

How long is the PM(NOC) stay?

Under s. 7(1)(d), the Minister may not issue the generic's notice of compliance until the day after a 24-month period that begins on the day the section 6 action is brought, unless the action ends earlier. The court can adjust the period if a party has not acted diligently or cooperated in expediting the action.

Which patents can be listed on the register?

Patents with claims to the medicinal ingredient, the formulation, the dosage form or the use of the medicinal ingredient, where that subject matter has been approved in the relevant submission. Certificates of supplementary protection can also be listed where the underlying patent is on the register.

Can an innovator sue later instead of within 45 days?

Generally not. Section 6.01 bars other infringement actions against the second person on patents that were the subject of a notice of allegation, unless the innovator lacked a reasonable basis to sue within the 45-day period. The decision to sue must be made promptly.

What are section 8 damages?

If a section 6 action is discontinued, dismissed or reversed on appeal, the plaintiffs are jointly liable for the generic's losses during the period it was kept off the market, usually from the later of service of the notice of allegation and the date the Minister certifies the NOC would otherwise have issued.

Sources

  1. Patented Medicines (Notice of Compliance) Regulations, SOR/93-133
  2. Patent Act, R.S.C. 1985, c. P-4
  3. AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36 (SCC docket 36654)

General information only, not legal advice. References to statutes, courts and authorities describe published law and practice at the date shown.